Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.61 |
| ▸ | PI4KA | P42356 | 6/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239755 | 0.82 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL14014060 | 0.79 | PI4KA (0.55) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL2980005 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18520815 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL25665342 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL8832637 | 0.79 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL13046992 | 0.79 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL9739976 | 0.77 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18165665 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22521611 | 0.77 | PI4KA (0.53) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2017176999-A1 | GLYCOSYLATED OLIGONUCLEOTIDES THAT MIMIC THE HIV-1 EPITOPE OF NEUTRAULIZING MONOCLONAL ANTIBODY 2G12 | BRANDEIS UNIVERSITY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20160304874-A1 | HIGH TEMPERATURE SELECTION OF NUCLEOTIDE-SUPPORTED CARBOHYDRATE VACCINES AND RESULTING GLYCOSYLATED OLIGONUCLEOTIDES | BRANDEIS UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| EP-2464651-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8912318-B2 | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2014-12-16 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | ADORA2A 2894/4885ADORA1 1579/4885ADORA2B 2198/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | ADORA2A 2439/4885ADORA1 1343/4885ADORA2B 1893/4885 |
| US-20160304874-A1 | HIGH TEMPERATURE SELECTION OF NUCLEOTIDE-SUPPORTED CARBOHYDRATE VACCINES AND RESULTING GLYCOSYLATED OLIGONUCLEOTIDES | RNGTT, BPGM, TLR9 | ADORA2A 265/4885ADORA1 269/4885ADORA2B 189/4885 |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | ADORA2A 1843/4885ADORA1 789/4885ADORA2B 490/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | ADORA2A 3693/4885ADORA1 2392/4885ADORA2B 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.